Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-6

Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2

Quick Stats
Studies 702
Trials 0
Score 3
2007 pubmed

Ghrelin and the enteroinsular axis in healthy men.

Micic. Dragan D; Duntas. Leonidas L; Cvijovic. Goran G; Kendereski. Aleksandra A; Sumarac-Dumanovic. Mirjana M; Jehle. Peter P; Zoric. Svetlana S; Pejkovic. Danica D; Lague. Mary M; Dieguez. Carlos C; Casanueva. Felipe F

Key Findings

  • A ghrelin bolus increased the overall exposure (AUC) to glucose and insulin during the test.
  • GLP‑1 levels fell after ghrelin administration, indicating reduced gut‑derived insulin‑stimulating signals.
  • No clear direct effect of ghrelin on other enteroinsular hormones, but ghrelin may boost the glucose‑insulin effect of GHRP‑6.

Practical Outcomes

  • When you use GHRP‑6, expect a modest rise in blood sugar and insulin, which could affect metabolic health, appetite, and weight control. Consider monitoring glucose/insulin if you’re sensitive to spikes, and maybe time GHRP‑6 doses around meals or combine with strategies that support stable blood sugar.

Summary

In healthy men, giving a ghrelin boost (the hormone that GHRP‑6 mimics) raised blood sugar and insulin levels and lowered the gut hormone GLP‑1. The study didn’t find a direct effect of ghrelin on other pancreatic hormones, but it suggests that ghrelin (and thus GHRP‑6) can amplify the glucose‑insulin response when used together with other growth‑hormone‑releasing agents.

Abstract

Ghrelin, a potent stimulator of GH secretion, also acts as an orexigenic hormone. Plasma ghrelin levels rise before meals with postprandial reduction, suggesting that circulating levels of enteroinsular hormones might influence ghrelin secretion. The aim of this study was to evaluate the effects of ghrelin on enteroinsular hormones in healthy men. Three tests were performed on 3 different days in 6 healthy men: On the first day, saline was infused from 0-120 minutes followed by a ghrelin bolus (1 microg/kg) administration (Test 1); on the second experimental day, GHRH was administered at 0 min, and a ghrelin bolus was given at 120 min (Test 2); on the third experimental day, GHRP-6 was administered at 0 min, followed by a ghrelin bolus at 120 min (Test 3). Plasma glucose, insulin, proinsulin, C-Peptide Glucagone Like Peptide one (GLP-1) determined at 0, 15, 30, 60, 90, and 120 min of the test period. There was a significant increase in AUC glucose (526.41+/-22.91 mmol . ml(-1) . min vs. 566.37+/-15.64 mmol . ml(-1) . min; p<0.05) and AUC insulin (756.25+/-107.56 mU . ml(-1) . min vs. 981.62+/-180.32 mU . ml(-1) . min; p<0.05) and a significant decrease in AUC GLP-1 (2346.87+/-874.28 pmol . ml(-1) . min vs. 1769.5+/-784 pmol . ml(-1) . min; p<0.05) after ghrelin administration in Test 1 compared to Test 3. There was a mild but non-significant increase in AUC for insulin, proinsulin, and C-Peptide and a mild reduction in AUC GLP-1 after every ghrelin administration. There was no evidence of a direct effect of ghrelin administration on enteroinsular hormone levels in this study. However, ghrelin may potentiate the glucose-insulin stimulatory effects of GHRP-6. More studies should be carried out for further evaluation of ghrelin-enteroinsular hormones interplay.

Study Information

Provider

pubmed

Year

2007

DOI

10.14310/horm.2002.1111028